Can SAM Segment Polyps?Tao Zhou, Yizhe Zhang, Yi Zhou et al.
Recently, Meta AI Research releases a general Segment Anything Model (SAM), which has demonstrated promising performance in several segmentation tasks. As we know, polyp segmentation is a fundamental task in the medical imaging field, which plays a critical role in the diagnosis and cure of colorectal cancer. In particular, applying SAM to the polyp segmentation task is interesting. In this report, we evaluate the performance of SAM in segmenting polyps, in which SAM is under unprompted settings. We hope this report will provide insights to advance this polyp segmentation field and promote more interesting works in the future. This project is publicly at https://github.com/taozh2017/SAMPolyp.
Structure-informed Language Models Are Protein DesignersZaixiang Zheng, Yifan Deng, Dongyu Xue et al.
This paper demonstrates that language models are strong structure-based protein designers. We present LM-Design, a generic approach to reprogramming sequence-based protein language models (pLMs), that have learned massive sequential evolutionary knowledge from the universe of natural protein sequences, to acquire an immediate capability to design preferable protein sequences for given folds. We conduct a structural surgery on pLMs, where a lightweight structural adapter is implanted into pLMs and endows it with structural awareness. During inference, iterative refinement is performed to effectively optimize the generated protein sequences. Experiments show that LM-Design improves the state-of-the-art results by a large margin, leading to up to 4% to 12% accuracy gains in sequence recovery (e.g., 55.65%/56.63% on CATH 4.2/4.3 single-chain benchmarks, and >60% when designing protein complexes). We provide extensive and in-depth analyses, which verify that LM-Design can (1) indeed leverage both structural and sequential knowledge to accurately handle structurally non-deterministic regions, (2) benefit from scaling data and model size, and (3) generalize to other proteins (e.g., antibodies and de novo proteins)